Immunomodulators Market Analysis By Product (Immunosuppressant, Immunostimulants, Vaccines, Antibodies), By Application (Oncology, Respiratory, HIV), By Region, And Segment Forecasts, 2014 - 2025
The global immunomodulators market is expected to reach USD 233.7 billion by 2025, according to a new study by Grand View Research, Inc. The market is anticipated to be predominantly driven by high R&D investments employed by the prominent companies, resulting into the large-scale production of new and therapeutically advanced drugs. This is believed to widen the influx of drugs at an unprecedented rate into the immunomodulators market hence providing highly efficacious treatment alternatives for numerous autoimmune and inflammatory diseases.
In addition, increasing drugs resistance is predicted to be responsible for boosting the clinical urgency to develop potentially new generation immunomodulators with targeted therapy mechanisms. The aforementioned factors cumulatively are expected to present significant growth opportunities over the forecast period.
Furthermore, burgeoning presence of the key players is expected to promote the awareness levels pertaining to benefits of immunomodulators amongst the patients as well as the physicians. This is further expected to widen the immunomodulators industry growth potential during the forecast period.
In addition, increasing adoption of monoclonal antibodies for a wide range of indications, such as, multiple sclerosis, Crohn’s disease, rheumatoid arthritis, and Non-Hodgkin’s Lymphoma, which is expected to boost immunomodulators industry over the forecast period. The consistent number of product approvals of highly significant monoclonal antibodies in autoimmune diseases is predicted to be responsible for widening the scope of growth.
Further Key Findings From the Study Suggest:
Immunosuppressant held the largest share of the product segment in 2015, owing to increasing number of transplantation procedures and need to prevent organ rejection
Antibodies held the dominant share of immunosuppressant in 2015, owing to extensive utilization in kidney, liver, heart, and lung transplants resulting in greater revenue generation
Immunostimulants expected to grow lucratively as a result of lower influx of immunostimulant generics for application in HIV, cancer and multiple sclerosis
In 2015, North America dominated the global immunomodulators market owing to presence of wide number of established pharmaceutical companies involved in extensive commercialization
The prominent participants are undertaking research and clinical collaborative strategies to yield new drugs and thereby to gain competitive advantage
For instance, in March 2015, Novartis AG entered into research collaboration with Aduro Biotech. This was carried out to enhance its next generation cancer immunotherapy product pipeline
In addition, increasing drugs resistance is predicted to be responsible for boosting the clinical urgency to develop potentially new generation immunomodulators with targeted therapy mechanisms. The aforementioned factors cumulatively are expected to present significant growth opportunities over the forecast period.
Furthermore, burgeoning presence of the key players is expected to promote the awareness levels pertaining to benefits of immunomodulators amongst the patients as well as the physicians. This is further expected to widen the immunomodulators industry growth potential during the forecast period.
In addition, increasing adoption of monoclonal antibodies for a wide range of indications, such as, multiple sclerosis, Crohn’s disease, rheumatoid arthritis, and Non-Hodgkin’s Lymphoma, which is expected to boost immunomodulators industry over the forecast period. The consistent number of product approvals of highly significant monoclonal antibodies in autoimmune diseases is predicted to be responsible for widening the scope of growth.
Further Key Findings From the Study Suggest:
Immunosuppressant held the largest share of the product segment in 2015, owing to increasing number of transplantation procedures and need to prevent organ rejection
Antibodies held the dominant share of immunosuppressant in 2015, owing to extensive utilization in kidney, liver, heart, and lung transplants resulting in greater revenue generation
Immunostimulants expected to grow lucratively as a result of lower influx of immunostimulant generics for application in HIV, cancer and multiple sclerosis
In 2015, North America dominated the global immunomodulators market owing to presence of wide number of established pharmaceutical companies involved in extensive commercialization
The prominent participants are undertaking research and clinical collaborative strategies to yield new drugs and thereby to gain competitive advantage
For instance, in March 2015, Novartis AG entered into research collaboration with Aduro Biotech. This was carried out to enhance its next generation cancer immunotherapy product pipeline
CHAPTER 1 RESEARCH METHODOLOGY & SCOPE
1.1 Region Wise Market Calculation
1.1.1 Region Wise Market: Base Estimates
1.1.2 Global Market: CAGR Calculation
1.2 Region-based segment share calculation
1.3 List of Secondary Sources
CHAPTER 2 EXECUTIVE SUMMARY
2.1 Market Snapshot
CHAPTER 3 IMMUNOMODULATORS MARKET VARIABLES, TRENDS & SCOPE
3.1 Market segmentation & scope
3.1.1 Market Driver Analysis
3.1.1.1 Increasing adoption of monoclonal antibodies
3.1.1.2 Rising incidence of cancer and other chronic conditions
3.1.1.3 Presence of strong pipeline portfolio
3.1.2 Market Restraint Analysis
3.1.2.1 High number of patent expiration
3.1.2.2 Growing generic & biosimilars competition
3.2 Penetration & Growth Prospect Mapping
3.3 Immunomodulators - PESTLE Analysis
3.4 Industry Analysis - Porter’s
CHAPTER 4 IMMUNOMODULATORS PRODUCT ESTIMATES & TREND ANALYSIS
4.1 Immunomodulators Market: Product Movement Analysis
4.2 Immunosuppressants
4.2.1 Immunosuppressants market, 2014 - 2025 (USD Billion)
4.2.2 Antibodies
4.2.2.1 Antibodies market, 2014 - 2025 (USD Billion)
4.2.3 Calcineurin inhibitors
4.2.3.1 Calcineurin inhibitors market, 2014 - 2025 (USD Billion)
4.2.4 Glucocorticoid
4.2.4.1 Antimetabolites market, 2014 - 2025 (USD Billion)
4.2.5 Antimetabolites
4.2.5.1 Antimetabolites market, 2014 - 2025 (USD Billion)
4.2.6 Others
4.2.6.1 Others market, 2014 - 2025 (USD Billion)
4.3 Immunostimulants
4.3.1 Immunostimulants market, 2014 - 2025 (USD Billion)
4.3.2 Vaccines
4.3.2.1 Vaccines market, 2014 - 2025 (USD Billion)
4.3.3 Antibodies
4.3.3.1 Antibodies market, 2014 - 2025 (USD Billion)
4.3.4 Others
4.3.4.1 Others market, 2014 - 2025 (USD Billion)
CHAPTER 5 IMMUNOMODULATORS APPLICATION ESTIMATES & TREND ANALYSIS
5.1 Immunomodulators Market: Application Movement Analysis
5.2 Oncology
5.2.1 Oncology s market, 2014 - 2025 (USD Billion)
5.3 Respiratory
5.3.1 Respiratory market, 2014 - 2025 (USD Billion)
5.4 HIV
5.4.1 HIV market, 2014 - 2025 (USD Billion)
5.5 Others
5.5.1 Others market, 2014 - 2025 (USD Billion)
CHAPTER 6 IMMUNOMODULATORS REGIONAL ESTIMATES & TREND ANALYSIS, BY PRODUCT AND APPLICATIONS
6.1 Immunomodulators market share by region, 2015 & 2024
6.2 North America
6.2.1 North America immunomodulators market, 2014 - 2025 (USD Billion)
6.2.2 U.S.
6.2.2.1 U.S. immunomodulators market, 2014 - 2025 (USD Billion)
6.2.3 Canada
6.2.3.1 Canada Immunomodulators market, 2014 - 2025 (USD Billion)
6.3 Europe
6.3.1 Europe Immunomodulators market, 2014 - 2025 (USD Billion)
6.3.2 UK
6.3.2.1 UK Immunomodulators market, 2014 - 2025 (USD Billion)
6.3.3 Germany
6.3.3.1 Germany Immunomodulators market, 2014 - 2025 (USD Billion)
6.4 Asia Pacific
6.4.1 Asia Pacific Immunomodulators market, 2014 - 2025 (USD Billion)
6.4.2 Japan
6.4.2.1 Japan Immunomodulators market, 2014 - 2025 (USD Billion)
6.4.3 China
6.4.3.1 China Immunomodulators market, 2014 - 2025 (USD Billion)
6.4.4 India
6.4.4.1 India Immunomodulators market, 2014 - 2025 (USD Billion)
6.5 Latin America
6.5.1 Latin America Immunomodulators market, 2014 - 2025 (USD Billion)
6.5.2 Brazil
6.5.2.1 Brazil Immunomodulators market, 2014 - 2025 (USD Billion)
6.5.3 Mexico
6.5.3.1 Mexico Immunomodulators market, 2014 - 2025 (USD Billion)
6.6 MEA
6.6.1 MEA Immunomodulators market, 2014 - 2025 (USD Billion)
6.6.2 South Africa
6.6.2.1 South Africa Immunomodulators market, 2014 - 2025 (USD Billion)
CHAPTER 7 COMPETITIVE LANDSCAPE
7.1 Strategy framework
7.2 Market participation categorization
7.3 Company Profiles
7.3.1 F. Hoffmann-La Roche Ltd.
7.3.1.1 Company Overview
7.3.1.2 Financial Performance
7.3.1.3 Product Benchmarking
7.3.1.4 Strategic Initiatives
7.3.2 Amgen, Inc.
7.3.2.1 Company Overview
7.3.2.2 Financial Performance
7.3.2.3 Product Benchmarking
7.3.2.4 Strategic Initiatives
7.3.3 Abbott
7.3.3.1 Company Overview
7.3.3.2 Financial Performance
7.3.3.3 ProductBenchmarking
7.3.3.4 Strategic Initiatives
7.3.4 Johnson & Johnson
7.3.4.1 Company Overview
7.3.4.2 Financial Performance
7.3.4.3 Product Benchmarking
7.3.4.4 Strategic Initiatives
7.3.5 Novartis AG
7.3.5.1 Company Overview
7.3.5.2 Financial Performance
7.3.5.3 Product Benchmarking
7.3.5.4 Strategic Initiatives
7.3.6 Eli Lilly and Company
7.3.6.1 Company Overview
7.3.6.2 Financial Performance
7.3.6.3 Product Benchmarking
7.3.7 Bristol-Myers Squibb Company
7.3.7.1 Company Overview
7.3.7.2 Financial Performance
7.3.7.3 Product Benchmarking
7.3.7.4 Strategic Initiatives
7.3.8 Merck & Co., Inc.
7.3.8.1 Company Overview
7.3.8.2 Financial Performance
7.3.8.3 Product Benchmarking
7.3.8.4 Strategic Initiatives
7.3.9 Biogen
7.3.9.1 Company Overview
7.3.9.2 Financial Performance
7.3.9.3 Product Benchmarking
7.3.9.4 Strategic Initiatives
1.1 Region Wise Market Calculation
1.1.1 Region Wise Market: Base Estimates
1.1.2 Global Market: CAGR Calculation
1.2 Region-based segment share calculation
1.3 List of Secondary Sources
CHAPTER 2 EXECUTIVE SUMMARY
2.1 Market Snapshot
CHAPTER 3 IMMUNOMODULATORS MARKET VARIABLES, TRENDS & SCOPE
3.1 Market segmentation & scope
3.1.1 Market Driver Analysis
3.1.1.1 Increasing adoption of monoclonal antibodies
3.1.1.2 Rising incidence of cancer and other chronic conditions
3.1.1.3 Presence of strong pipeline portfolio
3.1.2 Market Restraint Analysis
3.1.2.1 High number of patent expiration
3.1.2.2 Growing generic & biosimilars competition
3.2 Penetration & Growth Prospect Mapping
3.3 Immunomodulators - PESTLE Analysis
3.4 Industry Analysis - Porter’s
CHAPTER 4 IMMUNOMODULATORS PRODUCT ESTIMATES & TREND ANALYSIS
4.1 Immunomodulators Market: Product Movement Analysis
4.2 Immunosuppressants
4.2.1 Immunosuppressants market, 2014 - 2025 (USD Billion)
4.2.2 Antibodies
4.2.2.1 Antibodies market, 2014 - 2025 (USD Billion)
4.2.3 Calcineurin inhibitors
4.2.3.1 Calcineurin inhibitors market, 2014 - 2025 (USD Billion)
4.2.4 Glucocorticoid
4.2.4.1 Antimetabolites market, 2014 - 2025 (USD Billion)
4.2.5 Antimetabolites
4.2.5.1 Antimetabolites market, 2014 - 2025 (USD Billion)
4.2.6 Others
4.2.6.1 Others market, 2014 - 2025 (USD Billion)
4.3 Immunostimulants
4.3.1 Immunostimulants market, 2014 - 2025 (USD Billion)
4.3.2 Vaccines
4.3.2.1 Vaccines market, 2014 - 2025 (USD Billion)
4.3.3 Antibodies
4.3.3.1 Antibodies market, 2014 - 2025 (USD Billion)
4.3.4 Others
4.3.4.1 Others market, 2014 - 2025 (USD Billion)
CHAPTER 5 IMMUNOMODULATORS APPLICATION ESTIMATES & TREND ANALYSIS
5.1 Immunomodulators Market: Application Movement Analysis
5.2 Oncology
5.2.1 Oncology s market, 2014 - 2025 (USD Billion)
5.3 Respiratory
5.3.1 Respiratory market, 2014 - 2025 (USD Billion)
5.4 HIV
5.4.1 HIV market, 2014 - 2025 (USD Billion)
5.5 Others
5.5.1 Others market, 2014 - 2025 (USD Billion)
CHAPTER 6 IMMUNOMODULATORS REGIONAL ESTIMATES & TREND ANALYSIS, BY PRODUCT AND APPLICATIONS
6.1 Immunomodulators market share by region, 2015 & 2024
6.2 North America
6.2.1 North America immunomodulators market, 2014 - 2025 (USD Billion)
6.2.2 U.S.
6.2.2.1 U.S. immunomodulators market, 2014 - 2025 (USD Billion)
6.2.3 Canada
6.2.3.1 Canada Immunomodulators market, 2014 - 2025 (USD Billion)
6.3 Europe
6.3.1 Europe Immunomodulators market, 2014 - 2025 (USD Billion)
6.3.2 UK
6.3.2.1 UK Immunomodulators market, 2014 - 2025 (USD Billion)
6.3.3 Germany
6.3.3.1 Germany Immunomodulators market, 2014 - 2025 (USD Billion)
6.4 Asia Pacific
6.4.1 Asia Pacific Immunomodulators market, 2014 - 2025 (USD Billion)
6.4.2 Japan
6.4.2.1 Japan Immunomodulators market, 2014 - 2025 (USD Billion)
6.4.3 China
6.4.3.1 China Immunomodulators market, 2014 - 2025 (USD Billion)
6.4.4 India
6.4.4.1 India Immunomodulators market, 2014 - 2025 (USD Billion)
6.5 Latin America
6.5.1 Latin America Immunomodulators market, 2014 - 2025 (USD Billion)
6.5.2 Brazil
6.5.2.1 Brazil Immunomodulators market, 2014 - 2025 (USD Billion)
6.5.3 Mexico
6.5.3.1 Mexico Immunomodulators market, 2014 - 2025 (USD Billion)
6.6 MEA
6.6.1 MEA Immunomodulators market, 2014 - 2025 (USD Billion)
6.6.2 South Africa
6.6.2.1 South Africa Immunomodulators market, 2014 - 2025 (USD Billion)
CHAPTER 7 COMPETITIVE LANDSCAPE
7.1 Strategy framework
7.2 Market participation categorization
7.3 Company Profiles
7.3.1 F. Hoffmann-La Roche Ltd.
7.3.1.1 Company Overview
7.3.1.2 Financial Performance
7.3.1.3 Product Benchmarking
7.3.1.4 Strategic Initiatives
7.3.2 Amgen, Inc.
7.3.2.1 Company Overview
7.3.2.2 Financial Performance
7.3.2.3 Product Benchmarking
7.3.2.4 Strategic Initiatives
7.3.3 Abbott
7.3.3.1 Company Overview
7.3.3.2 Financial Performance
7.3.3.3 ProductBenchmarking
7.3.3.4 Strategic Initiatives
7.3.4 Johnson & Johnson
7.3.4.1 Company Overview
7.3.4.2 Financial Performance
7.3.4.3 Product Benchmarking
7.3.4.4 Strategic Initiatives
7.3.5 Novartis AG
7.3.5.1 Company Overview
7.3.5.2 Financial Performance
7.3.5.3 Product Benchmarking
7.3.5.4 Strategic Initiatives
7.3.6 Eli Lilly and Company
7.3.6.1 Company Overview
7.3.6.2 Financial Performance
7.3.6.3 Product Benchmarking
7.3.7 Bristol-Myers Squibb Company
7.3.7.1 Company Overview
7.3.7.2 Financial Performance
7.3.7.3 Product Benchmarking
7.3.7.4 Strategic Initiatives
7.3.8 Merck & Co., Inc.
7.3.8.1 Company Overview
7.3.8.2 Financial Performance
7.3.8.3 Product Benchmarking
7.3.8.4 Strategic Initiatives
7.3.9 Biogen
7.3.9.1 Company Overview
7.3.9.2 Financial Performance
7.3.9.3 Product Benchmarking
7.3.9.4 Strategic Initiatives
LIST OF TABLES
TABLE 1 North America immunomodulators market, by product, 2014 - 2025 (USD Billion)
TABLE 2 North America immunosuppressants market, by type, 2014 - 2025 (USD Billion)
TABLE 3 North America immunostimulants market, by type, 2014 - 2025 (USD Billion)
TABLE 4 North America immunomodulators market, by applications, 2014 - 2025 (USD Billion)
TABLE 5 U.S. immunomodulators market, by product, 2014 - 2025 (USD Billion)
TABLE 6 U.S. immunosuppressants market, by type, 2014 - 2025 (USD Billion)
TABLE 7 U.S. immunostimulants market, by type, 2014 - 2025 (USD Billion)
TABLE 8 U.S. immunomodulators market, by applications, 2014 - 2025 (USD Billion)
TABLE 9 Canada immunomodulators market, by product, 2014 - 2025 (USD Billion)
TABLE 10 Canada immunosuppressants market, by type, 2014 - 2025 (USD Billion)
TABLE 11 Canada immunostimulants market, by type, 2014 - 2025 (USD Billion)
TABLE 12 Canada immunomodulators market, by applications, 2014 - 2025 (USD Billion)
TABLE 13 Europe immunomodulators market, by product, 2014 - 2025 (USD Billion)
TABLE 14 Europe immunosuppressants market, by type, 2014 - 2025 (USD Billion)
TABLE 15 Europe immunostimulants market, by type, 2014 - 2025 (USD Billion)
TABLE 16 Europe immunomodulators market, by applications, 2014 - 2025 (USD Billion)
TABLE 17 UK immunomodulators market, by product, 2014 - 2025 (USD Billion)
TABLE 18 UK immunosuppressants market, by type, 2014 - 2025 (USD Billion)
TABLE 19 UK immunostimulants market, by type, 2014 - 2025 (USD Billion)
TABLE 20 UK immunomodulators market, by applications, 2014 - 2025 (USD Billion)
TABLE 21 Germany immunomodulators market, by product, 2014 - 2025 (USD Billion)
TABLE 22 Germany immunosuppressants market, by type, 2014 - 2025 (USD Billion)
TABLE 23 Germany immunostimulants market, by type, 2014 - 2025 (USD Billion)
TABLE 24 Germany immunomodulators market, by applications, 2014 - 2025 (USD Billion)
TABLE 25 Asia Pacific immunomodulators market, by product, 2014 - 2025 (USD Billion)
TABLE 26 Asia Pacific immunosuppressants market, by type, 2014 - 2025 (USD Billion)
TABLE 27 Asia Pacific immunostimulants market, by type, 2014 - 2025 (USD Billion)
TABLE 28 Asia Pacific immunomodulators market, by applications, 2014 - 2025 (USD Billion)
TABLE 29 Japan immunomodulators market, by product, 2014 - 2025 (USD Billion)
TABLE 30 Japan immunosuppressants market, by type, 2014 - 2025 (USD Billion)
TABLE 31 Japan immunostimulants market, by type, 2014 - 2025 (USD Billion)
TABLE 32 Japan immunomodulators market, by applications, 2014 - 2025 (USD Billion)
TABLE 33 China immunomodulators market, by product, 2014 - 2025 (USD Billion)
TABLE 34 China immunosuppressants market, by type, 2014 - 2025 (USD Billion)
TABLE 35 China immunostimulants market, by type, 2014 - 2025 (USD Billion)
TABLE 36 China immunomodulators market, by applications, 2014 - 2025 (USD Billion)
TABLE 37 India immunomodulators market, by product, 2014 - 2025 (USD Billion)
TABLE 38 India immunosuppressants market, by type, 2014 - 2025 (USD Billion)
TABLE 39 India immunostimulants market, by type, 2014 - 2025 (USD Billion)
TABLE 40 India immunomodulators market, by applications, 2014 - 2025 (USD Billion)
TABLE 41 Latin America immunomodulators market, by product, 2014 - 2025 (USD Billion)
TABLE 42 Latin America immunosuppressants market, by type, 2014 - 2025 (USD Billion)
TABLE 43 Latin America immunostimulants market, by type, 2014 - 2025 (USD Billion)
TABLE 44 Latin America immunomodulators market, by applications, 2014 - 2025 (USD Billion)
TABLE 45 Brazil immunomodulators market, by product, 2014 - 2025 (USD Billion)
TABLE 46 Brazil immunosuppressants market, by type, 2014 - 2025 (USD Billion)
TABLE 47 Brazil immunostimulants market, by type, 2014 - 2025 (USD Billion)
TABLE 48 Brazil immunomodulators market, by applications, 2014 - 2025 (USD Billion)
TABLE 49 Mexico immunomodulators market, by product, 2014 - 2025 (USD Billion)
TABLE 50 Mexico immunosuppressants market, by type, 2014 - 2025 (USD Billion)
TABLE 51 Mexico immunostimulants market, by type, 2014 - 2025 (USD Billion)
TABLE 52 Mexico immunomodulators market, by applications, 2014 - 2025 (USD Billion)
TABLE 53 MEA immunomodulators market, by product, 2014 - 2025 (USD Billion)
TABLE 54 MEA immunosuppressants market, by type, 2014 - 2025 (USD Billion)
TABLE 55 MEA immunostimulants market, by type, 2014 - 2025 (USD Billion)
TABLE 56 MEA immunomodulators market, by applications, 2014 - 2025 (USD Billion)
TABLE 57 South Africa immunomodulators market, by product, 2014 - 2025 (USD Billion)
TABLE 58 South Africa immunosuppressants market, by type, 2014 - 2025 (USD Billion)
TABLE 59 South Africa immunostimulants market, by type, 2014 - 2025 (USD Billion)
TABLE 60 South Africa immunomodulators market, by applications, 2014 - 2025 (USD Billion)
TABLE 1 North America immunomodulators market, by product, 2014 - 2025 (USD Billion)
TABLE 2 North America immunosuppressants market, by type, 2014 - 2025 (USD Billion)
TABLE 3 North America immunostimulants market, by type, 2014 - 2025 (USD Billion)
TABLE 4 North America immunomodulators market, by applications, 2014 - 2025 (USD Billion)
TABLE 5 U.S. immunomodulators market, by product, 2014 - 2025 (USD Billion)
TABLE 6 U.S. immunosuppressants market, by type, 2014 - 2025 (USD Billion)
TABLE 7 U.S. immunostimulants market, by type, 2014 - 2025 (USD Billion)
TABLE 8 U.S. immunomodulators market, by applications, 2014 - 2025 (USD Billion)
TABLE 9 Canada immunomodulators market, by product, 2014 - 2025 (USD Billion)
TABLE 10 Canada immunosuppressants market, by type, 2014 - 2025 (USD Billion)
TABLE 11 Canada immunostimulants market, by type, 2014 - 2025 (USD Billion)
TABLE 12 Canada immunomodulators market, by applications, 2014 - 2025 (USD Billion)
TABLE 13 Europe immunomodulators market, by product, 2014 - 2025 (USD Billion)
TABLE 14 Europe immunosuppressants market, by type, 2014 - 2025 (USD Billion)
TABLE 15 Europe immunostimulants market, by type, 2014 - 2025 (USD Billion)
TABLE 16 Europe immunomodulators market, by applications, 2014 - 2025 (USD Billion)
TABLE 17 UK immunomodulators market, by product, 2014 - 2025 (USD Billion)
TABLE 18 UK immunosuppressants market, by type, 2014 - 2025 (USD Billion)
TABLE 19 UK immunostimulants market, by type, 2014 - 2025 (USD Billion)
TABLE 20 UK immunomodulators market, by applications, 2014 - 2025 (USD Billion)
TABLE 21 Germany immunomodulators market, by product, 2014 - 2025 (USD Billion)
TABLE 22 Germany immunosuppressants market, by type, 2014 - 2025 (USD Billion)
TABLE 23 Germany immunostimulants market, by type, 2014 - 2025 (USD Billion)
TABLE 24 Germany immunomodulators market, by applications, 2014 - 2025 (USD Billion)
TABLE 25 Asia Pacific immunomodulators market, by product, 2014 - 2025 (USD Billion)
TABLE 26 Asia Pacific immunosuppressants market, by type, 2014 - 2025 (USD Billion)
TABLE 27 Asia Pacific immunostimulants market, by type, 2014 - 2025 (USD Billion)
TABLE 28 Asia Pacific immunomodulators market, by applications, 2014 - 2025 (USD Billion)
TABLE 29 Japan immunomodulators market, by product, 2014 - 2025 (USD Billion)
TABLE 30 Japan immunosuppressants market, by type, 2014 - 2025 (USD Billion)
TABLE 31 Japan immunostimulants market, by type, 2014 - 2025 (USD Billion)
TABLE 32 Japan immunomodulators market, by applications, 2014 - 2025 (USD Billion)
TABLE 33 China immunomodulators market, by product, 2014 - 2025 (USD Billion)
TABLE 34 China immunosuppressants market, by type, 2014 - 2025 (USD Billion)
TABLE 35 China immunostimulants market, by type, 2014 - 2025 (USD Billion)
TABLE 36 China immunomodulators market, by applications, 2014 - 2025 (USD Billion)
TABLE 37 India immunomodulators market, by product, 2014 - 2025 (USD Billion)
TABLE 38 India immunosuppressants market, by type, 2014 - 2025 (USD Billion)
TABLE 39 India immunostimulants market, by type, 2014 - 2025 (USD Billion)
TABLE 40 India immunomodulators market, by applications, 2014 - 2025 (USD Billion)
TABLE 41 Latin America immunomodulators market, by product, 2014 - 2025 (USD Billion)
TABLE 42 Latin America immunosuppressants market, by type, 2014 - 2025 (USD Billion)
TABLE 43 Latin America immunostimulants market, by type, 2014 - 2025 (USD Billion)
TABLE 44 Latin America immunomodulators market, by applications, 2014 - 2025 (USD Billion)
TABLE 45 Brazil immunomodulators market, by product, 2014 - 2025 (USD Billion)
TABLE 46 Brazil immunosuppressants market, by type, 2014 - 2025 (USD Billion)
TABLE 47 Brazil immunostimulants market, by type, 2014 - 2025 (USD Billion)
TABLE 48 Brazil immunomodulators market, by applications, 2014 - 2025 (USD Billion)
TABLE 49 Mexico immunomodulators market, by product, 2014 - 2025 (USD Billion)
TABLE 50 Mexico immunosuppressants market, by type, 2014 - 2025 (USD Billion)
TABLE 51 Mexico immunostimulants market, by type, 2014 - 2025 (USD Billion)
TABLE 52 Mexico immunomodulators market, by applications, 2014 - 2025 (USD Billion)
TABLE 53 MEA immunomodulators market, by product, 2014 - 2025 (USD Billion)
TABLE 54 MEA immunosuppressants market, by type, 2014 - 2025 (USD Billion)
TABLE 55 MEA immunostimulants market, by type, 2014 - 2025 (USD Billion)
TABLE 56 MEA immunomodulators market, by applications, 2014 - 2025 (USD Billion)
TABLE 57 South Africa immunomodulators market, by product, 2014 - 2025 (USD Billion)
TABLE 58 South Africa immunosuppressants market, by type, 2014 - 2025 (USD Billion)
TABLE 59 South Africa immunostimulants market, by type, 2014 - 2025 (USD Billion)
TABLE 60 South Africa immunomodulators market, by applications, 2014 - 2025 (USD Billion)
LIST OF FIGURES
FIG. 1 Market summary
FIG. 2 Market trends & outlook
FIG. 3 Market segmentation & scope
FIG. 4 Market driver relevance analysis (Current & future impact)
FIG. 5 Market restraint relevance analysis (Current & future impact)
FIG. 6 Penetration & Growth Prospect Mapping
FIG. 7 Immunomodulators PESTLE Analysis
FIG. 8 Porter’s Five Forces Analysis
FIG. 9 Immunomodulators market product outlook key takeaways
FIG. 10 Immunomodulators market: Drug class movement analysis
FIG. 11 Immunosuppressants market, 2014 - 2025 (USD Billion)
FIG. 12 Antibodies market, 2014 - 2025 (USD Billion)
FIG. 13 Calcineurin inhibitors market, 2014 - 2025 (USD Billion)
FIG. 14 Glucocorticoid market, 2014 - 2025 (USD Billion)
FIG. 15 Antimetabolites market, 2014 - 2025 (USD Billion)
FIG. 16 Others market, 2014 - 2025 (USD Billion)
FIG. 17 Immunostimulants market, 2014 - 2025 (USD Billion)
FIG. 18 Vaccines market, 2014 - 2025 (USD Billion)
FIG. 19 Antibodies market, 2014 - 2025 (USD Billion)
FIG. 20 Others market, 2014 - 2025 (USD Billion)
FIG. 21 Immunomodulators market application outlook key takeaways
FIG. 22 Immunomodulators market: Indications movement analysis
FIG. 23 Oncology market, 2014 - 2025 (USD Billion)
FIG. 24 Respiratory market, 2014 - 2025 (USD Billion)
FIG. 25 HIV market, 2014 - 2025 (USD Billion)
FIG. 26 Others market, 2014 - 2025 (USD Billion)
FIG. 27 Regional marketplace: Key takeaways
FIG. 28 Regional outlook, 2015 & 2024
FIG. 29 North America immunomodulators market, 2014 - 2025 (USD Billion)
FIG. 30 U.S. immunomodulators market, 2014 - 2025 (USD Billion)
FIG. 31 Canada Immunomodulators market, 2014 - 2025 (USD Billion)
FIG. 32 Europe Immunomodulators market, 2014 - 2025 (USD Billion)
FIG. 33 UK Immunomodulators market, 2014 - 2025 (USD Billion)
FIG. 34 Germany Immunomodulators market, 2014 - 2025 (USD Billion)
FIG. 35 Asia Pacific Immunomodulators market, 2014 - 2025 (USD Billion)
FIG. 36 Japan Immunomodulators market, 2014 - 2025 (USD Billion)
FIG. 37 China Immunomodulators market, 2014 - 2025 (USD Billion)
FIG. 38 India Immunomodulators market, 2014 - 2025 (USD Billion)
FIG. 39 Latin America Immunomodulators market, 2014 - 2025 (USD Billion)
FIG. 40 Brazil Immunomodulators market, 2014 - 2025 (USD Billion)
FIG. 41 Mexico Immunomodulators market, 2014 - 2025 (USD Billion)
FIG. 42 MEA Immunomodulators market, 2014 - 2025 (USD Billion)
FIG. 43 South Africa Immunomodulators market, 2014 - 2025 (USD Billion)
FIG. 44 Strategy framework
FIG. 45 Participant categorization
FIG. 1 Market summary
FIG. 2 Market trends & outlook
FIG. 3 Market segmentation & scope
FIG. 4 Market driver relevance analysis (Current & future impact)
FIG. 5 Market restraint relevance analysis (Current & future impact)
FIG. 6 Penetration & Growth Prospect Mapping
FIG. 7 Immunomodulators PESTLE Analysis
FIG. 8 Porter’s Five Forces Analysis
FIG. 9 Immunomodulators market product outlook key takeaways
FIG. 10 Immunomodulators market: Drug class movement analysis
FIG. 11 Immunosuppressants market, 2014 - 2025 (USD Billion)
FIG. 12 Antibodies market, 2014 - 2025 (USD Billion)
FIG. 13 Calcineurin inhibitors market, 2014 - 2025 (USD Billion)
FIG. 14 Glucocorticoid market, 2014 - 2025 (USD Billion)
FIG. 15 Antimetabolites market, 2014 - 2025 (USD Billion)
FIG. 16 Others market, 2014 - 2025 (USD Billion)
FIG. 17 Immunostimulants market, 2014 - 2025 (USD Billion)
FIG. 18 Vaccines market, 2014 - 2025 (USD Billion)
FIG. 19 Antibodies market, 2014 - 2025 (USD Billion)
FIG. 20 Others market, 2014 - 2025 (USD Billion)
FIG. 21 Immunomodulators market application outlook key takeaways
FIG. 22 Immunomodulators market: Indications movement analysis
FIG. 23 Oncology market, 2014 - 2025 (USD Billion)
FIG. 24 Respiratory market, 2014 - 2025 (USD Billion)
FIG. 25 HIV market, 2014 - 2025 (USD Billion)
FIG. 26 Others market, 2014 - 2025 (USD Billion)
FIG. 27 Regional marketplace: Key takeaways
FIG. 28 Regional outlook, 2015 & 2024
FIG. 29 North America immunomodulators market, 2014 - 2025 (USD Billion)
FIG. 30 U.S. immunomodulators market, 2014 - 2025 (USD Billion)
FIG. 31 Canada Immunomodulators market, 2014 - 2025 (USD Billion)
FIG. 32 Europe Immunomodulators market, 2014 - 2025 (USD Billion)
FIG. 33 UK Immunomodulators market, 2014 - 2025 (USD Billion)
FIG. 34 Germany Immunomodulators market, 2014 - 2025 (USD Billion)
FIG. 35 Asia Pacific Immunomodulators market, 2014 - 2025 (USD Billion)
FIG. 36 Japan Immunomodulators market, 2014 - 2025 (USD Billion)
FIG. 37 China Immunomodulators market, 2014 - 2025 (USD Billion)
FIG. 38 India Immunomodulators market, 2014 - 2025 (USD Billion)
FIG. 39 Latin America Immunomodulators market, 2014 - 2025 (USD Billion)
FIG. 40 Brazil Immunomodulators market, 2014 - 2025 (USD Billion)
FIG. 41 Mexico Immunomodulators market, 2014 - 2025 (USD Billion)
FIG. 42 MEA Immunomodulators market, 2014 - 2025 (USD Billion)
FIG. 43 South Africa Immunomodulators market, 2014 - 2025 (USD Billion)
FIG. 44 Strategy framework
FIG. 45 Participant categorization
